Status:

COMPLETED

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes

Healthy

Eligibility:

MALE

18-55 years

Phase:

PHASE1

Brief Summary

This trial is conducted in Europe. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 70 in healthy male subjects.

Eligibility Criteria

Inclusion

  • Considered generally healthy upon completion of medical history and physical examination, as judged by the investigator
  • Body Mass Index (BMI) between 19.0-30.0 kg/m\^2
  • Glycohemoglobin (HbA1c) within laboratory normal range
  • Non-smokers

Exclusion

  • Clinically significant abnormal haematology, biochemistry, urinalysis or ECG (electrocardiogram) screening tests, as judged by the investigator
  • Liver enzyme values (ALAT and ASAT) exceeding 2 times the upper reference limit according to the local laboratory
  • A history of any illness that, in the opinion of the Investigator and/or Sponsor, might confound the results of the trial or pose additional risk in administering the investigational product to the subject
  • History of or current addiction to alcohol or drugs of abuse as determined by the investigator (positive urine drug screen and breath alcohol screen)
  • HIV (human immunodeficiency virus), Hepatitis B or C positive
  • Subjects with a first-degree relative with diabetes mellitus
  • A history of multiple and/or severe allergies to drugs or foods or a history of anaphylactic reactions
  • Known or suspected allergy to trial product or related products
  • Smoking during the past three months

Key Trial Info

Start Date :

December 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2004

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT01527656

Start Date

December 1 2003

End Date

February 1 2004

Last Update

January 6 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novo Nordisk Investigational Site

Neuss, Germany, 41460